Difference between revisions of "Carmustine wafer, polifeprosan 20 (Gliadel wafer)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m
Line 14: Line 14:
 
*[http://chemocare.com/chemotherapy/drug-info/carmustine-wafer.aspx Carmustine wafer, polifeprosan 20 (Gliadel) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/carmustine-wafer.aspx Carmustine wafer, polifeprosan 20 (Gliadel) patient drug information (Chemocare)]</ref>
 
*[http://chemocare.com/chemotherapy/drug-info/carmustine-wafer.aspx Carmustine wafer, polifeprosan 20 (Gliadel) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/carmustine-wafer.aspx Carmustine wafer, polifeprosan 20 (Gliadel) patient drug information (Chemocare)]</ref>
 
*[http://www.uptodate.com/contents/carmustine-patient-drug-information Carmustine wafer, polifeprosan 20 (Gliadel) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/carmustine-patient-drug-information Carmustine wafer, polifeprosan 20 (Gliadel) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/carmustine-patient-drug-information Carmustine wafer, polifeprosan 20 (Gliadel) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/carmustine-patient-drug-information Carmustine wafer, polifeprosan 20 (Gliadel) patient drug information (UpToDate)]</ref>
 +
 +
==History of changes in FDA indication==
 +
* 9/23/1996: Inital FDA approval
  
 
==References==
 
==References==
Line 23: Line 26:
 
[[Category:Alkylating agents]]
 
[[Category:Alkylating agents]]
 
[[Category:Central nervous system (CNS) cancer medications]]
 
[[Category:Central nervous system (CNS) cancer medications]]
 +
 +
[[Category:Drugs FDA approved in 1996]]

Revision as of 15:13, 7 November 2014

Also known as Gliadel wafer or polifeprosan 20 with carmustine implant.

General information

Class/mechanism: Biodegradable copolymer matrix (polifeprosan 20) embedded with carmustine, a nitrosourea which alkylates DNA and RNA and inhibits several key enzymatic processes by carbamoylation of amino acids in proteins. Each Gliadel wafer is 1.45 cm in diameter and 1 mm thick and contains 192.3 mg copolymer and 7.7 mg carmustine. Exposure to the surgical resection cavity results in hydrolyzation of anhydride bonds of the copolymer, which releases carmustine.[1][2][3]
Route: implanted wafer
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 9/23/1996: Inital FDA approval

References